USA flag logo/image

An Official Website of the United States Government

Robust Wide-Angle Spectral Domain OCT Arthroscope for Operative Imaging and…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88831
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
AR056194
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOPTIGEN, INC.
BPX 13569 DURHAM, NC -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Robust Wide-Angle Spectral Domain OCT Arthroscope for Operative Imaging and Guida
Agency: HHS
Contract: 1R43AR056194-01
Award Amount: $201,230.00
 

Abstract:

DESCRIPTION (provided by applicant): This Phase I Small Business Innovative Research application proposes to develop a robust spectral domain optical coherence tomography (SDOCT) system suitable for combined diagnosis and treatment monitoring of osteoarthr itis. Osteoarthritis is reaching epidemic proportions in the United States. Difficulty in diagnosing cartilage degeneration prior to the development of irreversible changes is a major obstacle to development and evaluation of disease modifying treatments f or osteoarthritis. The earliest signs of degeneration occur prior to breakdown of the articular surface and include microstructural changes that are difficult to detect by radiographs, standard arthroscopy, or conventional magnetic resonance imaging (MRI). Orthopaedic surgeons perform over 650,000 arthroscopies a year for knee problems and find visible cartilage damage in up to 80% of patients. Professor Constance Chu, a subcontractor on this application, has shown that OCT can be used arthroscopically to n ondestructively image articular cartilage at resolutions comparable to low power histology, and that OCT detectable changes found in the laboratory to indicate potentially reversible early cartilage insensitivity to anabolic growth factors were more preval ent in patients undergoing arthroscopic surgery for conditions associated with early degenerative joint disease. Because early chondrocyte metabolic incompetence has been implicated in the pathogenesis of osteoarthritis, these findings support the hypothes is that OCT can be used clinically to improve arthroscopic diagnosis of early articular cartilage degeneration. This proposal aims to develop novel clinical technology for arthroscopic OCT by developing new rigid borescope technology for sub-surface visual ization of cartilage surfaces, synergizing the OCT probe with arthroscopic tools used for debridement, and reconfiguration/miniaturization of components to permit easy and frequent sterilization of the entire probe.

Principal Investigator:

Business Contact:


ebuckland@bioptigen.com
Small Business Information at Submission:

BIOPTIGEN, INC.
BIOPTIGEN, INC. BPX 13569 DURHAM, NC 27709

EIN/Tax ID: 156247672
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No